An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2018
At a glance
- Drugs CA-4948 (Primary)
- Indications Acute myeloid leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Curis
- 15 Aug 2018 Planned number of patients changed from 120 to 80.
- 02 Aug 2018 According to a Curis media release, the company is extending this Phase I clinical trial to enrol a cohort of patients with acute myeloid leukemia (AML), an update is expected in 2H 2018.
- 18 Jan 2018 Status changed from not yet recruiting to recruiting.